CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | |
| 424B4 | 2026-05-13 | English | |
| Regulatory Filings 2026 | 2026-05-12 | English | |
| S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | |
| DEL AM | 2026-04-24 | English | |
| S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 45766521 | 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | ||
| 46081758 | 424B4 | 2026-05-13 | English | ||
| 46081745 | Regulatory Filings 2026 | 2026-05-12 | English | ||
| 39639190 | S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | ||
| 46081761 | DEL AM | 2026-04-24 | English | ||
| 34662842 | S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | ||
| 32880286 | 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | ||
| 18269065 | 4 Filing | 2026-01-26 | English | ||
| 18269090 | 4 Filing | 2026-01-05 | English | ||
| 18269058 | 4 Filing | 2026-01-05 | English | ||
| 18269037 | 4 Filing | 2026-01-05 | English | ||
|
2025
4 filings
| |||||
| 18269100 | 10-K Filing | 2025-12-29 | English | ||
| 9417629 | PRIMARY DOCUMENT | 2025-12-05 | English | ||
| 9417630 | Regulatory Filings 2025 | 2025-12-04 | English | ||
| 9417631 | FORM 8-K | 2025-11-24 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
OS Therapies Inc
Clinical-stage immunotherapy company developing treatments …
|
OSTX | US | Professional, scientific and te… |
|
Ovation Science Inc.
Develops and licenses patented Invisicare® technology for e…
|
OVAT | CA | Professional, scientific and te… |
|
OXFORD BIODYNAMICS PLC
Develops and commercializes precision medicine tests for on…
|
OBD | GB | Professional, scientific and te… |
|
Oxurion NV
Acquires majority stakes in European pharmaceutical subcont…
|
OXUR | BE | Professional, scientific and te… |
|
PACIFIC EDGE LIMITED
Develops non-invasive molecular tests for bladder cancer de…
|
PEB | NZ | Professional, scientific and te… |
|
PARADIGM BIOPHARMACEUTICALS LIMITED..
Repurposing PPS for osteoarthritis and rare inflammatory di…
|
PAR | AU | Professional, scientific and te… |
|
Pasithea Therapeutics Corp.
Develops treatments for central nervous system disorders, R…
|
KTTA | US | Professional, scientific and te… |
|
Passage BIO, Inc.
A clinical-stage genetic medicines company developing thera…
|
PASG | US | Professional, scientific and te… |
|
PATRYS LIMITED
Develops Deoxymab antibody therapies targeting DNA repair m…
|
PAB | AU | Professional, scientific and te… |
|
PAVmed Inc.
A diversified medical technology company developing devices…
|
PAVM | US | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.